Aster DM Healthcare (ASTERDM) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
3 Jun, 2026Strategic vision and values
Committed to accessible, affordable quality healthcare with a global vision and strong core values of excellence, respect, compassion, passion, integrity, and unity.
Business overview and operational scale
Operates 20 hospitals with 5,449 beds across 16 cities and 5 states, supported by 10 clinics, 304 labs, and 203 pharmacies as of March 2026.
Achieved 61% occupancy, 3.1 days average length of stay, and INR 51,800 ARPOB in FY26.
Revenue reached INR 4,643 Cr in FY26, with a 3-year CAGR of 16% and operating EBITDA margin of 20.4%.
Merger with Quality Care India Limited (QCIL)
Approved merger with QCIL, creating one of India's top 3 hospital chains with 10,623 beds and INR 9,273 Cr revenue.
Merged entity, Aster DM Quality Care Limited, will have 57.3% Aster and 42.7% QCIL shareholding.
Merger is cash neutral, expected to be EPS accretive from the first full year, and jointly controlled by Aster promoters and Blackstone.
Latest events from Aster DM Healthcare
- Robust revenue and EBITDA growth, with the Quality Care merger and expansion fueling future gains.ASTERDM
Q4 25/261 May 2026 - 15% revenue and 22% EBITDA growth, merger progress, and major internal restructuring.ASTERDM
Q3 25/2610 Apr 2026 - FY25 profit surged on 12% revenue growth, margin gains, and QCIL merger, with strong dividends.ASTERDM
Q4 24/253 Feb 2026 - Q1 FY25 delivered 20% revenue growth, record profit, and expansion after GCC business sale.ASTERDM
Q1 24/252 Feb 2026 - Strong revenue, profit, and margin growth, boosted by GCC separation and cluster performance.ASTERDM
Q2 24/2519 Jan 2026 - Merger forms a top-three Indian hospital chain with 10,150+ beds and strong EBITDA synergies.ASTERDM
M&A Announcement12 Jan 2026 - Revenue and EBITDA surged, margins expanded, and a major merger and restructuring advanced.ASTERDM
Q3 24/259 Jan 2026 - Revenue and margin rose strongly, with QCIL merger, asset expansion, and dividend plans advanced.ASTERDM
Q1 25/2616 Nov 2025 - Q2 saw double-digit growth, margin gains, and major merger progress with expansion plans.ASTERDM
Q2 25/267 Nov 2025